[Henoch-schönlein purpura induced by erlotinib (Tarceva): a case report].

Erlotinib is a newly developed molecular-targeting or molecular-targeted drug with selective inhibitory activity for tyrosine kinase of the epidermal growth factor receptor. A adverse drug reactions including diarrhea, skin eruptions are considered mild. We report a case of recurrent adenocarcinoma of the lung in a 68-year-old woman who suffered from Henoch-Schönlein purpura induced by erlotinib.

Primary cutaneous anaplastic large cell lymphoma associated with vascular endothelial growth factor arising from a burn scar.

We present a case of primary cutaneous anaplastic large cell lymphoma manifesting with widespread erythema around an ulcer. Skin biopsy from the ulcer showed CD30-positive atypical lymphocytes throughout the dermis, and immunostaining demonstrated that these cells produced vascular endothelial growth factor, a potent stimulus for angiogenesis. Skin biopsy from the erythema revealed rich neovascularization, which was probably associated with vascular endothelial growth factor.

Cutaneous tissue angiotensin-converting enzyme may participate in pathologic scar formation in human skin.

Background: Many studies have shown that up-regulation of angiotensin-converting enzyme (ACE) participates in adverse fibrous remodeling. Although this has become an accepted fact in the cardiovascular field, the relationship between ACE and cutaneous fibrous remodeling, such as keloid or hypertrophic scars, remains unknown.

Objective: We sought to investigate ACE in normal skin, wounded skin, and pathologic scars.